Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cingal for Knee Osteoarthritis
NCT04231318Phase 3Completed
- Sponsor
- Anika Therapeutics
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Injectable Hydrogels, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone hexacetonide + hyaluronic acid in osteoarthritis (OA) (3 arms), sponsored by Anika Therapeutics. Primary endpoint: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score at 26 weeks. Started Sep 2020; status: completed.
02
Drugs
triamcinolone hexacetonide + hyaluronic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04231318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231318.